Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

GW Pharmaceuticals PLC (GWPH) Stock Sinks As Market Gains: What You Should Know

Published 02/11/2019, 05:45 AM
Updated 07/09/2023, 06:31 AM
US500
-
DJI
-

GW Pharmaceuticals PLC (GWPH) closed the most recent trading day at $144.55, moving -1.51% from the previous trading session. This change lagged the S&P 500's 0.07% gain on the day. Elsewhere, the Dow lost 0.21%, while the tech-heavy Nasdaq added 0.13%.

Heading into today, shares of the company had gained 17.09% over the past month, outpacing the Medical sector's gain of 3.05% and the S&P 500's gain of 5.36% in that time.

Investors will be hoping for strength from GWPH as it approaches its next earnings release, which is expected to be February 26, 2019. On that day, GWPH is projected to report earnings of -$2.97 per share, which would represent a year-over-year decline of 22.22%. Meanwhile, our latest consensus estimate is calling for revenue of $9.28 million, up 19.99% from the prior-year quarter.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$10.18 per share and revenue of $96.16 million. These totals would mark changes of +3.6% and +467.12%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for GWPH. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.43% higher within the past month. GWPH is holding a Zacks Rank of #2 (Buy) right now.

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 36% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.



GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.